Last reviewed · How we verify
ITI-1284
At a glance
| Generic name | ITI-1284 |
|---|---|
| Sponsor | Intra-Cellular Therapies, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease (PHASE2)
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia (PHASE2)
- Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (PHASE2)
- Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder (PHASE2)
- A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects (PHASE1)
- PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |